Navigation Links
Protein prevents detrimental immune effects of bacterial sepsis

The anti-inflammatory protein annexin 1 may protect patients from the detrimental effects of severe inflammatory response syndrome, as reported by researchers at Barts and the London, Queen Mary's School of Medicine and Dentistry. The paper by Damazo et al., "Critical protective role for annexin 1 gene expression in the endotoxemic murine microcirculation," appears in the June issue of The American Journal of Pathology and is accompanied by a commentary.

Severe inflammatory response syndrome, or SIRS, occurs when the body's response to an overwhelming infection becomes uncontrolled. The very immune response meant to clear the pathogen and its toxins actually causes damage to the host's own tissues when it goes into overdrive, releasing too many immune signals. Thus, the immune response must be carefully controlled to prevent damage to the host.

Damazo et al. studied this balancing act by analyzing the effects of the bacterial toxin LPS on normal and annexin 1 knockout mice. Annexin 1 was chosen because it appears to be involved in the resolution phase of the immune response: its expression on white blood cells impairs their ability to bind blood vessel walls, preventing their transit from the blood to other organs.

When normal mice were treated with LPS, the immune system induced a steady migration of white blood cells from the blood into affected tissues. However, mice deficient for annexin 1 exhibited a dramatic release of white blood cells from blood vessels, ultimately leading to 100% mortality by 48 hours.

The researchers characterized the expression of annexin 1 and found that the gene was activated as early as 1.5 and 6 hours after LPS administration, with levels returning to normal by 24 hours. Higher levels of markers of inflammation, and of organ injury, were measured in annexin 1 deficient animals. Altogether, these findings implied that the protective effects of the annexin 1 pathway were activated in the first few hours fo llowing toxin administration. In fact, when annexin 1 knockout mice were given small doses of human recombinant annexin 1 in the first 24 hours following LPS treatment, survival increased to 60%.

These results, obtained in the lab of Dr. Mauro Perretti, highlight the delicate balance between the "pro-inflammatory/detrimental vs. anti-inflammatory/protective phases" of the immune response. Dr Perretti explained, "For too long, we have ignored anti-inflammatory/counter-regulatory mediators and the impact they have on pathology outcome; studying the way our body controls responses to infections can allow the modeling of new therapeutics with lower side effects."

The importance of this work is underscored by the fact that bacterial sepsis ranked among the top ten causes of death in both adults and neonates in 2002 in the United States (Natl Vital Stat Rep 2005, 53:1-89). The patients at greatest risk of developing sepsis and SIRS are those with impaired immune systems. When such patients are unable to control the underlying bacterial infection, their immune systems overcompensate and trigger a dangerous cascade of tissue damage.

Thus, to prevent death from sepsis, physicians must not only control the bacterial infection but better control the detrimental effects of the immune system. Dr. Perretti's lab is further investigating these immune pathways: "The ultimate goal is to use these new targets (e.g., a receptor for a given anti-inflammatory mediator) to develop better and safer drugs." The data for annexin 1 provide a new direction for such therapeutics that delicately balances removal of bacterial toxins and damage to host tissues.


Source:American Journal of Pathology

Related biology news :

1. Quantum Dots Research Leads to New Knowledge about Protein Binding in Plants
2. Protein discovery could unlock the secret to better TB treatment
3. Researchers Uncover Key Step In Manufacture of Memory Protein
4. An HIV Protein Plays a Surprising Role in Gene Activation
5. Protein Packages Found To Activate Genes; May Be What Regulates Development And Disease
6. New SARS Protein Linked To Important Cell Doorway
7. The Shapes Of Life: NIGMS Project Yields More Than 1,000 Protein Structures
8. PANTHER Protein Classification System Database 5.0
9. Duke Chemists Isolating Individual Molecules Of Toxic Protein In Alzheimers, Parkinsons Disease
10. Newly Discovered Compound Blocks Known Cancer-Causing Protein
11. UF Researchers Map Bacterial Proteins That Cause Tooth Loss
Post Your Comments:

(Date:10/2/2015)... , Oct. 02 2015 ... the "Enforcing the Law Using Biometrics" ... ) has announced the addition of the ... their offering. --> Research and Markets ... the "Enforcing the Law Using Biometrics" ...
(Date:9/30/2015)... BEACH GARDENS, Fla. , Sept. 30, 2015 /PRNewswire/ ... earlier this month issued another key ruling in favor ... (ITC,s) determination that Korean fingerprint scanner company Suprema and ... Tariff Act of 1930, a trade provision that declares ... with import trade, by infringing two of Crossmatch,s patents, ...
(Date:9/29/2015)... 29, 2015  iDAvatars is excited to be named one ... to market. The official announcement was recently made at an ... in San Francisco , where iDAvatars presented ... IBM Watson. "It is both an honor and ... to bring to market the cognitive power of IBM Watson ...
Breaking Biology News(10 mins):
(Date:10/13/2015)... , Oct. 13, 2015 Applied BioMath ( ... critical decision points throughout the drug invention process, announced ... Boston 2015 on October 20-22, 2015 in ... PhD, Co-Founder, President, and CEO of Applied BioMath, will ... early research to clinical trials" on Wednesday October 21st ...
(Date:10/13/2015)... SAN DIEGO , Oct. 13, 2015 ... to collaborate in the development of a higher purity ... BASF under the Kolliphor ® P188 brand, is ... biological applications, such as a shear protectant in cell ... Mast,s lead product candidate. Under the agreement between BASF ...
(Date:10/13/2015)... Mass. and TORONTO , Oct. ... GNBT) today announced that it has entered into a non-binding ... ), a private Israeli company that has developed a proprietary ... infertile due to varicoceles. the United States ... between the ages of 25 and 44 diagnosed ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... personalized medicine, is excited to announce their partnership with the Keck Medicine ... genetics of chronic pain. , The T.R.O.J.A.N. Study (Therapeutic Evaluation to Research Clinical ...
Breaking Biology Technology: